132 related articles for article (PubMed ID: 18937971)
1. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
Ziółkowska-Seta I; Madry R; Kraszewska E; Szymańska T; Timorek A; Rembiszewska A; Kupryjańczyk J
Gynecol Oncol; 2009 Jan; 112(1):179-84. PubMed ID: 18937971
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.
Kupryjańczyk J; Szymańska T; Madry R; Timorek A; Stelmachów J; Karpińska G; Rembiszewska A; Ziółkowska I; Kraszewska E; Debniak J; Emerich J; Ułańska M; Płuzańska A; Jedryka M; Goluda M; Chudecka-Głaz A; Rzepka-Górska I; Klimek M; Urbański K; Breborowicz J; Zieliński J; Markowska J
Br J Cancer; 2003 Mar; 88(6):848-54. PubMed ID: 12644821
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
4. TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.
Kupryjanczyk J; Kraszewska E; Ziolkowska-Seta I; Madry R; Timorek A; Markowska J; Stelmachow J; Bidzinski M;
BMC Cancer; 2008 Jan; 8():27. PubMed ID: 18230133
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.
Malamou-Mitsi V; Crikoni O; Timotheadou E; Aravantinos G; Vrettou E; Agnantis N; Fountzilas G
Anticancer Res; 2007; 27(2):1157-65. PubMed ID: 17465257
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
[TBL] [Abstract][Full Text] [Related]
9. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
[TBL] [Abstract][Full Text] [Related]
10. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
11. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
[TBL] [Abstract][Full Text] [Related]
14. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
15. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
16. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
[TBL] [Abstract][Full Text] [Related]
17. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of advanced ovarian cancer.
Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers.
Lee YK; Park NH
Gynecol Oncol; 2009 Mar; 112(3):475-80. PubMed ID: 19150122
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
